occurring in 53.2% of patients with DC and 59.1% in UC. Recurrent use of corticosteroids (27.7% in CD and 27.9% in UC) followed by treatment de-escalation (29.8% in DC and 22.7% in UC) were also causes of treatment modification. Currently, 21.4% of patients with CD use immunosuppressants as monotherapy and 44.6% use biologicals as monotherapy compared to UC, where 0% and 3% use immunosuppressants or biologics as monotherapy (P < 0.001). In UC, 30.3% use 5-methotrexate acid (5-ASA) as monotherapy, 15.2% require combined therapy with 5-ASA and immunosuppressants and 9.1% require combined therapy with biological, immunosuppressants and 5-ASA. Corticosteroids are still being used in combination with 5-ASA in 24.2% of this sample. Median time until biological prescription was 14 months, and 159 in CD and UC respectively (P = 0.511).

CONCLUSION: In this study, most patients required treatment modification, most cases due to lack of response. This finding highlights the severity of PBD, where immunosuppression and combined therapy are often required. Monotherapy was statically more frequent in CD than UC. This probably reflects different misinterpretation in immune response in UC. Use of corticosteroids was also more frequently seen in UC than CD.

P069
Admission Steroid Use, Serum Albumin and Endoscopic Severity Predict IntraVenous Steroid Failure in Patients With Acute Severe Ulcerative Colitis
Subhannah Delahania1, Kakkaadam Ramaswamy Pradeep1, Shukla Dheeraj1, Motett Haddi1, Bhullar Manecha1, Ishaq Naveed1, Mcivor Carolyn1, Edwards John1, Mohsen Wael1, 2
Gold Coast University Hospital, Gold Coast, Queensland, Australia, 3Logan Hospital, Meadowbrook, Queensland, Australia.

BACKGROUND: About 40% of patients with acute severe ulcerative colitis (ASUC) fail cortico-steroid therapy, hence it is important to develop criteria which can predict steroid failure earlier. Our aim was to identify variables (clinical, biochemical and endoscopic) and develop a novel day 1 score for predicting steroid failure.

METHODS: All patients admitted for ASUC (fulfilling Truelove and Witts Criteria) between January 1, 2015 and July 30, 2020 at GCUH and From January 1, 2018 to July 31, 2020 at LGH were retrospectively analysed. Review of electronic medical records was performed and clinical, endoscopic, laboratory data were collected. Steroid failure was defined as need for rescue therapy (medical or surgical). For comparisons of proportions, we used Pearson’s Chi square test or Fisher’s exact tests. Quantitative data were compared using t-test or Wilcoxon rank sum test. To test independent predictive factors, a logistic regression model was constructed with the requirement for rescue therapy as the dependent variable.

RESULTS: There were 194 episodes of 194 participants of ASUC included. Seventy-seven (50.3%) were 60 years of age, steroid failure rate, the need for colectomy during the same admission and colectomy at 12 months is similar to a population.

P071
Fistula Healing After Fecal Diversification Surgery in Perianal Crohn’s Disease; A Case Series
Johnson Shek1, Ko Jee2, Halabi Yissum2, Stendell Jesse1, Dave Maneche1
1University of California, Davis, Sacramento, United States. 2Background: Fistulas are seen in 25% of patients with Crohn’s disease and are often refractory to medical therapy. Fecal diversion is used to treat perianal fistula, with 63% in clinical improvement, however data on fistula healing rates are often not reported. This case series aims to evaluate the response of complete fistula healing in complex perianal Crohn’s disease after fecal diversification.

METHODS: Patients with perianal Crohn’s disease who underwent fecal diversification surgery from June 1, 2016 to June 1, 2020 with colorectal surgeons at UC Davis were selected through electronic medical record chart extraction using ICD-10 and CPT codes.

RESULTS: Ten patients were referred for refractory perianal fistula undergoing fecal diversification surgery from June 1, 2016 to June 1, 2020. Fistula healing was evaluated through imaging or exam under anesth- esia. One patient was lost to follow up after surgery and not included in the outcomes. Time to follow up ranged from 4 to 24 months, with a mean of 11 months. Patient were aged 22–60 years, 5/11 patients were females. Ten of 11 patients were undergoing steroid therapy at time of surgery. 4/10 (40%) had complete fistula healing, 6/10 (60%) had persistent fistula, and 3/10 (30%) were readmitted within 90 days for complications. Most frequent complications observed were peristomal wounds/skin infection (3/10), high ostomy output/dehydration (2/10), bowel obstruction (1/10). Two patients required proctectomy.

CONCLUSION: Fistula healing rates after fecal diversions were low, at 40% and is accompanied by frequent complications such as output high ostomy.

P072
The Pathway IBD Care in Rio de Janeiro From a Tertiary Referral Center Point of View
Gomes Rafaela Roberta1, Nolasco Mateus Victor1, Azevedo Junior Pradeep1, Mohsen Wael2, 3
1Division of Gastroenterology, Internal Medicine, Catholic University of Rio de Janeiro, Rio de Janeiro, Brazil, 2Vniversidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.

BACKGROUND: It’s well-established that both Crohn’s disease and ulcerative colitis are a public health challenge worldwide.1 The complexity of the diagnosis and the lack of familiarity of care practitioners with the different IBD phenotypes can cause a delay in IBD recognition, referral to an appropriate care, and consequently, time of this study was להת應用 העילא לתשובהatient care pathway since first symptoms until attendance in a tertiary IBD outpatient unit.

METHODS: Retrospective cohort study involving outpatients from a reference IBD unit from a tertiary care center from 2015 to 2018. The data collected through structured interviews and medical record review were: sex, age at diagnosis, family history, initial diagnosis, the interval between symptoms onset and definitive diagnosis, disease type and phenotype, extra-intestinal manifestations (EM), number of medical appointments until definitive diagnosis, type of health system unit where the diagnosis occurred, and first treatment. Statistics were performed using SPSS® software.

RESULTS: There were 188 participants included, 99 (52.6%) with CD and 89 (47.4%) with UC, the majority female (56.4%) with a predominant age group of 17–40 years in both diseases (72.7% CD, 52.8% UC). Family IBD history was more frequent in CD (21.2% vs 12.1%) (P = 0.08). Predominant initial treatment in the UC was with aminosalicylates (39.8%), whereas in CD, the use of symptomatic treatments (24.2%) prevailed. In both diseases, the presumptive IBD diagnosis was made in the private health system (40.4% CD, 46.1% UC), but the definitive diagnosis occurred mainly at the university public hospital (CD = 60.6% vs 21.2%, UC = 50.6% vs 31.5% UC, re- spectively), not occurring in basic care units. The earlier diagnosis (less than a year) was more significantly obtained in UC (50.6%) in comparison to CD patients (28.3%) (P = 0.001). The first symptoms in CD were in decreasing order: abdominal pain (78.8%), diarrhea (70.7%), and weight loss (63.6%); and in UC: rectal bleeding (80.9%), diarrhea (76.4%), and abdominal pain (33.9%). EIM was present in 43.7% UC and 34.4% CD, with a higher frequency of rheumatological manifestations in both diseases (DC 23.2%, UC 23.1%).

CONCLUSION: Despite the predominance of classic initial symptoms, the diagnosis of IBD was complex and mostly made in reference centers with a significant delay, mainly in CD patients. The introduction of new treatment during the therapeutic window of opportunity in early disease modifies progressive course of disease, delaying or preventing complications and patient’s quality of life. However, the local expertise, availability of minimal testing resources and an IBD care pathway with standardized referral patterns are necessary to provide an earlier diagnosis and treatment.

P073
Analysis of Dysbiosis in Crohn’s Disease by Next-Generation Sequencing: One Size Does Not Fit All
Papoutsis Andreas1, Haizen Sabrina1, Carlos Edmilson2
1University of Florida, Gainesville, Florida, United States. 2Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.

BACKGROUND: Crohn's disease is a complex chronic inflammatory condition of the gastrointestinal tract. Diagnosis is often challenging due to the overlap of symptoms with other gastrointestinal diseases. Microbiome dysbiosis has been implicated in the pathogenesis of Crohn’s disease (CD). The gut microbiome is a complex ecosystem that is highly influenced by many factors such as age, gender, lifestyle, diet, and environment. The specific composition of the gut microbiome can vary greatly between individuals, and it is hypothesized that a specific gut microbiome composition may be associated with CD.

OBJECTIVES: We aimed to investigate the gut microbiome composition in CD patients using Next-Generation Sequencing (NGS).

METHODS: We recruited 20 patients with confirmed CD diagnosis, and 20 healthy controls (HC). The gut microbiome was sequenced using Illumina MiSeq platform. The sequencing data were analyzed using QIIME2 software. We performed alpha and beta diversity analysis, and compared the microbiome composition between CD and HC using ANOVA and post-hoc Tukey-Kramer tests.

RESULTS: The gut microbiome composition differed significantly between CD and HC. The CD group had a significantly lower richness and diversity compared to HC, with a higher abundance of pathogenic bacteria such as Enterobacteriaceae and Bacteroides. In contrast, the HC group had a higher abundance of beneficial bacteria such as Lactobacillus and Bifidobacterium.

CONCLUSION: The gut microbiome composition differs significantly between CD and HC, with a higher abundance of pathogenic bacteria in CD patients. These findings support the hypothesis that microbiome dysbiosis plays a role in the pathogenesis of CD. Further studies are needed to validate these findings and to explore the potential therapeutic interventions targeting the gut microbiome.